Marty Reiswig is fit and healthy, but every two weeks he is injected with the experimental drug gantenerumab and has monthly MRI scans. He submits to this because a rare genetic mutation runs in his family that predisposes them to early-onset Alzheimer’s disease.We spoke to him about his experience on the trial, and why he chose to continue trialling the drug even after formal clinical trials were discontinued.Produced and narrated by Lorna Stewart.More on this story:News Feature: <a href="https://www.nature.com/articles/d41586-022-00651-0" rel="noopener noreferrer" target="_blank">Could drugs prevent Alzheimer’s? These trials aim to find out</a>Resources for those affected by Alzheimer's:<a href="https://www.alz.org/help-support/resources" rel="noopener noreferrer" target="_blank">Alzheimer's association</a><a href="https://www.alzheimers.gov/" rel="noopener noreferrer" target="_blank">Alzheimers.gov</a><a href="https://www.alzheimers.org.uk/get-support" rel="noopener noreferrer" target="_blank">Alzheimer's society</a><hr> See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for privacy and opt-out information.

Podurama

Home

Trending

Personal

Your Podcasts

New Episodes

My Files

Favourite Episodes

Tags (Folders)

Recently Played

Bookmarks

Followed Playlists

The coin toss of Alzheimer's inheritance

Nature Podcast